Literature DB >> 11050475

Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor.

N Nakayashiki1, K Yoshikawa, K Nakamura, N Hanai, K Okamoto, S Okamoto, M Mizuno, T Wakabayashi, S Saga, J Yoshida, T Takahashi.   

Abstract

The type III deletion mutant of the epidermal growth factor receptor (EGFR) is a potential target in diagnostic and therapeutic approaches for those glioblastomas characterized by its expression. We previously raised a mouse monoclonal antibody, 3C10 (IgG2b) specifically recognizing this mutant EGFR. In this study, a single-chain variable fragment (scFv) antibody was produced. Partial determination of its N-terminal amino acid sequence and preparation of adequate primers for variable heavy chain (V(H)) and variable light chain (V(L)) genes were performed to allow cloning by means of reverse transcriptase-polymerase chain reaction. The genes cloned were assembled with a linker, (Gly4Ser)3, and ligated into a bacterial expression vector to express the scFv as cytoplasmic inclusion bodies. After appropriate refolding, the antibody activity of the V(H)-V(L) scFv was examined in an enzyme-linked immunosorbent assay. 3C10 scFv showed a selective reactivity with the mutant peptide, similarly to the parental 3C10 antibody. A mouse transfectant expressing the type III mutant EGFR and a glioblastoma with type III deletion-mutant EGFR were positively stained by immunofluorescence. By Biacore analysis, the affinity (K(A)) of the parental 3C10 for the mutant peptide was 9.7 x 10(7) M(-1), while that of 3C10 scFv was 2.45 - 2.48 x 10(7) M(-1), being approximately 4-fold weaker. The results together suggested that the scFv antibody retained the appropriate structure to recognize a conformational epitope of the mutant receptor, similarly to the parental antibody.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050475      PMCID: PMC5926257          DOI: 10.1111/j.1349-7006.2000.tb00882.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  21 in total

Review 1.  Biosynthetic antibody binding sites: development of a single-chain Fv model based on antidinitrophenol IgA myeloma MOPC 315.

Authors:  J E McCartney; L Lederman; E A Drier; N A Cabral-Denison; G M Wu; R S Batorsky; J S Huston; H Oppermann
Journal:  J Protein Chem       Date:  1991-12

Review 2.  New protein engineering approaches to multivalent and bispecific antibody fragments.

Authors:  A Plückthun; P Pack
Journal:  Immunotechnology       Date:  1997-06

3.  Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.

Authors:  I A Lorimer; A Keppler-Hafkemeyer; R A Beers; C N Pegram; D D Bigner; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.

Authors:  P A Humphrey; L M Gangarosa; A J Wong; G E Archer; M Lund-Johansen; R Bjerkvig; O D Laerum; H S Friedman; D D Bigner
Journal:  Biochem Biophys Res Commun       Date:  1991-08-15       Impact factor: 3.575

5.  125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.

Authors:  C T Kuan; C J Reist; C F Foulon; I A Lorimer; G Archer; C N Pegram; I Pastan; M R Zalutsky; D D Bigner
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

6.  Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.

Authors:  S H Bigner; P A Humphrey; A J Wong; B Vogelstein; J Mark; H S Friedman; D D Bigner
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

7.  Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody.

Authors:  D Hills; G Rowlinson-Busza; W J Gullick
Journal:  Int J Cancer       Date:  1995-11-15       Impact factor: 7.396

8.  Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

Authors:  C J Wikstrand; L P Hale; S K Batra; M L Hill; P A Humphrey; S N Kurpad; R E McLendon; D Moscatello; C N Pegram; C J Reist
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

9.  A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors.

Authors:  H Yamazaki; Y Ohba; N Tamaoki; M Shibuya
Journal:  Jpn J Cancer Res       Date:  1990-08

10.  Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor.

Authors:  S Okamoto; K Yoshikawa; Y Obata; M Shibuya; S Aoki; J Yoshida; T Takahashi
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

View more
  7 in total

1.  Construction, expression and tumor targeting of a single-chain Fv against human colorectal carcinoma.

Authors:  Jin Fang; Hong-Bin Jin; Jin-Dan Song
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

2.  Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Authors:  Richard A Morgan; Laura A Johnson; Jeremy L Davis; Zhili Zheng; Kevin D Woolard; Elizabeth A Reap; Steven A Feldman; Nachimuthu Chinnasamy; Chien-Tsun Kuan; Hua Song; Wei Zhang; Howard A Fine; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2012-09-24       Impact factor: 5.695

3.  Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor.

Authors:  Syuntaro Takasu; Toshitada Takahashi; Sho Okamoto; Noboru Oriuchi; Norihisa Nakayashiki; Kenta Okamoto; Hideki Muramatsu; Takeshi Hayashi; Norimoto Nakahara; Masaaki Mizuno; Toshihiko Wakabayashi; Tetsuya Higuchi; Keigo Endo; Kenichi Kozaki; Osamu Miyaishi; Shinsuke Saga; Ryuzo Ueda; Jun Yoshida; Kazuhiro Yoshikawa
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.130

4.  Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.

Authors:  S Kuramitsu; M Ohno; F Ohka; S Shiina; A Yamamichi; A Kato; K Tanahashi; K Motomura; G Kondo; M Kurimoto; T Senga; T Wakabayashi; A Natsume
Journal:  Cancer Gene Ther       Date:  2015-10-09       Impact factor: 5.987

5.  Phage display cloning and characterization of monoclonal antibody genes and recombinant Fab fragment against the CD98 oncoprotein.

Authors:  K Itoh; K Inoue; K Hirooka; K Maruyama; M Ohkawa; K Matsui; H Tada; T Enomoto; Y Hashimoto; T Suzuki; T Masuko
Journal:  Jpn J Cancer Res       Date:  2001-12

6.  Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.

Authors:  Tsutomu Nakazawa; Atsushi Natsume; Fumihiko Nishimura; Takayuki Morimoto; Ryosuke Matsuda; Mitsutoshi Nakamura; Shuichi Yamada; Ichiro Nakagawa; Yasushi Motoyama; Young-Soo Park; Takahiro Tsujimura; Toshihiko Wakabayashi; Hiroyuki Nakase
Journal:  Cells       Date:  2020-04-16       Impact factor: 6.600

7.  Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts.

Authors:  Masasuke Ohno; Takayuki Ohkuri; Akemi Kosaka; Kuniaki Tanahashi; Carl H June; Atsushi Natsume; Hideho Okada
Journal:  J Immunother Cancer       Date:  2013-12-16       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.